Hartland/Imtesty, 

This is just one of many reviews/research articles on BET inhibitors to be published recently. It is well known that pan BET inhibitors have some problems. Published clinical studies with first generation inhibitors cause certain unavoidable side effects warranting intermittent treatment (i.e two weeks on drug one week off). These side effects are likely going to occur with all pan BET inhibitors because these are on-target side effect. It's also been published that certain cancers develop resistance to BET inhibitors. Some cancers, but not all. This article was focused on AML. Pre-treatment patient screening and knowledge of cancer type can help here. And it is not too surprising that combo therapies would work better than single agent therapies. 

So what exactly in this abstract is bothering you?